Tissue Collection for Cutaneous T-Cell Lymphoma

Recruiting at 1 trial location

Overseen By Larisa J Geskin, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Columbia University

Must not be taking: Systemic immunosuppressive, biologic

Disqualifiers: Previous lymphoma, HIV, anemia, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

400 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to better understand changes in T cells in individuals with Cutaneous T-cell lymphoma (CTCL), a type of skin cancer. Researchers will collect and store tissue samples from patients with CTCL, as well as control subjects with or without certain skin conditions like eczema. Suitable participants include those with CTCL, Lymphomatoid Papulosis (LYP), or Sézary Syndrome (SS) who are starting or changing their treatment, as well as individuals with benign skin conditions.

As an unphased trial, this study offers a unique opportunity to contribute to scientific understanding and potentially improve future treatments.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the study team or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on collecting tissue samples for Cutaneous T-cell Lymphoma (CTCL), which can significantly enhance our understanding of the disease. Unlike existing treatments that directly target the symptoms or progression of CTCL, this repository aims to gather comprehensive data to identify new biomarkers and potential therapeutic targets. By analyzing these tissue samples, scientists hope to uncover novel insights that could lead to the development of more effective and personalized treatment options in the future.

Who Is on the Research Team?

Larisa J. Geskin, MD

Principal Investigator

Columbia University

Are You a Good Fit for This Trial?

Inclusion Criteria

Patients with CTCL or Lymphomatoid Papulosis (LYP): a clinical or histologic diagnosis of a) newly diagnosed, b) progressive, or c) relapsed CTCL or LYP who are initiating or changing therapy.

Patients with Sézary Syndrome (SS) or stage IV B CTCL as defined by blood involvement on flow cytometry or morphology: (1) ≥1000/μL Sézary cells by morphology; (2) Cluster of differentiation 4 (CD4)/cluster of differentiation 8 (CD8) ratio ≥10; (3) CD4+cluster of differentiation 7 (CD7)- cells ≥40 percent; (4) or CD4+cluster of differentiation 26 (CD26)- cells ≥30 percent.

Ability to understand and willing to sign a willing informed consent document.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection

Collection and storage of tissue samples from CTCL patients and control patients

2 years

Follow-up

Participants are monitored for safety and effectiveness after sample collection

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Tissue Collection

Who Is Running the Clinical Trial?

Columbia University

Lead Sponsor

Trials

1,529

Recruited

2,832,000+